When should SGLT2 inhibitors be initiated in adults with chronic kidney disease, what are the recommended doses and monitoring parameters, and under what conditions should therapy be discontinued?

SGLT2 Inhibitors in Chronic Kidney Disease

Initiate SGLT2 inhibitors in all adults with CKD and eGFR ≥20 ml/min/1.73 m² regardless of diabetes status, with strongest recommendations for those with albuminuria ≥200 mg/g or heart failure. 1

When to Initiate

Strong Recommendations (1A Evidence)

• eGFR ≥20 ml/min/1.73 m² WITH any of the following:
  • Type 2 diabetes 1
  • Urine ACR ≥200 mg/g (≥20 mg/mmol) 1
  • Heart failure (regardless of albuminuria level) 1

Weaker Recommendation (2B Evidence)

• eGFR 20-45 ml/min/1.73 m² with ACR <200 mg/g 1

Risk-Stratified Approach

The 2024 BMJ guideline provides an alternative framework based on KDIGO risk stratification 2:

• High to very high risk of CKD progression: Strong recommendation
• Low to moderate risk: Weak recommendation in favor

This applies to all adults with CKD regardless of diabetes status, emphasizing that benefits extend beyond glucose control to mortality, cardiovascular events, and kidney failure prevention 2.

Dosing

Use standard approved doses without adjustment for mild-to-moderate CKD. Drug exposure increases modestly as eGFR declines, but this does not require dose reduction 3, 4. The glucose-lowering effect diminishes with declining eGFR, but cardiovascular and renal protective effects persist 3, 5.

Common agents:

• Dapagliflozin: 10 mg daily
• Empagliflozin: 10-25 mg daily
• Canagliflozin: 100 mg daily (can increase to 300 mg if eGFR >60)

Monitoring Parameters

SGLT2 inhibitor initiation does not require altered frequency of routine CKD monitoring. 1

Key Monitoring Points

• The reversible eGFR dip after initiation is expected and NOT an indication to stop therapy 1
• Continue standard CKD monitoring intervals based on baseline kidney function
• Monitor for:
  • Genital mycotic infections (increased risk: RR 2.40) 6
  • Volume depletion/hypotension (modestly increased risk: RR 1.28) 6
  • Euglycemia in patients with diabetes

When to Continue vs. Discontinue

Continue Therapy

Once initiated, continue SGLT2 inhibitors even when eGFR falls below 20 ml/min/1.73 m² until dialysis or transplantation. 1, 7

This recommendation is supported by post-hoc analysis of CREDENCE showing persistent cardiovascular and kidney benefits with no additional safety concerns when eGFR declined <20 ml/min/1.73 m² 7.

Temporarily Withhold During

• Prolonged fasting 1
• Surgery 1
• Critical medical illness (when at greater risk for ketosis) 1

Recent evidence suggests continuation may be safe in hemodynamically stable hospitalized patients, though this requires clinical judgment 8.

Discontinue When

• Kidney replacement therapy (dialysis) is initiated 1
• Intolerance develops 1
• Unmanageable recurrent genital infections
• Recurrent volume depletion despite appropriate management

Critical Practice Points

Common Pitfalls to Avoid

1. Do NOT stop therapy for the initial eGFR dip - this is an expected hemodynamic effect that does not indicate harm 1
2. Do NOT restrict use based on diabetes status - benefits extend to non-diabetic CKD 2, 1
3. Do NOT wait for severe albuminuria - initiate based on eGFR and risk stratification 1
4. Do NOT discontinue when eGFR falls below initiation threshold - continue until dialysis 1, 7

Safety Profile

The safety profile remains favorable across the CKD spectrum 6:

• Genital mycotic infections are manageable and should not preclude use
• Volume depletion risk is modest and can be managed with patient education
• No increased risk of acute kidney injury 6
• Diabetic ketoacidosis is very rare 6

Special Populations

Elderly patients (≥65 years): Full renal and cardiovascular benefits are maintained with manageable safety profile, supporting routine use with stratified monitoring 6.